EZH2 and uveal melanoma: We extended our pharmacological observations to another malignancy, uveal melanoma, which also shows a high frequency of mutations in BAP1. Like mesothelioma, only BAP1-deficient, and not WT, uveal melanoma cell lines are sensitive to combined treatment with EZH2 and mevalonate pathway inhibitors (Figures 4B and S4K–S4S).